Abstract | Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the laboratory, but none have translated to positive results in patients with PD. Potential neuroprotective drugs, such as ubiquinone, creatine and PYM50028, have failed to show any clinical benefits in recent high-profile clinical trials. This 'failure to translate' is likely to be related primarily to our incomplete understanding of the pathogenic mechanisms underlying PD, and excessive reliance on data from toxin-based animal models to judge which agents should be selected for clinical trials. Restricted resources inevitably mean that difficult compromises must be made in terms of trial design, and reliable estimation of efficacy is further hampered by the absence of validated biomarkers of disease progression. Drug development in PD dementia has been mostly unsuccessful; however, emerging biochemical, genetic and pathological evidence suggests a link between tau and amyloid-β deposition and cognitive decline in PD, potentially opening up new possibilities for therapeutic intervention. This Review discusses the most important 'druggable' disease mechanisms in PD, as well as the most-promising drugs that are being evaluated for their potential efficiency in treatment of motor and cognitive impairments in PD.
Introduction
Despite the obvious need for neuroprotective or diseasemodifying agents for Parkinson disease (PD), and the great promise that many potential therapies have shown in preclinical studies, no treatments have been licensed as neuroprotective agents in PD. Despite strong in vitro and in vivo data, several notable candidate neuroprotective drugs have failed to show benefits in recent high-profile phase I and/or II clinical trials (Table 1) . This discrepancy between encouraging preclinical data and failure to translate the results to therapies that would be efficacious in patients requires continuous reappraisal. Rather than analysing the reasons for the failure of each of these specific agents, this Review provides a general discussion of the obstacles that continue to impede the development of neuroprotective agents. In this context, we summarize the current status of the most promising candidate therapies that are currently being evaluated in clinical trials for neuro protective or disease-modifying effects in PD, and assess their therapeutic potential.
To date, clinical trials have mainly focused on preserving motor function, which has, historically, been easier to quantify than nonmotor symptoms. However, validated tools to assess nonmotor symptoms are now becoming available, and these symptoms-in particular, cognitive dysfunction-are increasingly recognized as important contributors to quality of life in patients with PD. Nonmotor symptoms are only partially responsive to dopaminergic therapy, and they remain largely refractory to current interventions. 1, 2 Of specific relevance is the growing evidence that Alzheimer disease (AD)-like pathology-amyloid-β (Aβ) plaques and hyper phosphorylated tau-containing neurofibrillary tangles-contributes to cognitive dysfunction in PD. To this end, we discuss whether targeting of tau and repurposing of AD disease-modifying treatments could improve cognitive dysfunction in patients with PD.
abnormal protein aggregation to be elucidated in single cells. Also, the development of transgenic animal models that express genes associated with PD in humans provides an opportunity to gain a greater insight into the molecular mechanisms of PD pathogenesis, such as cellto-cell transmission of α-synuclein. Improved understanding of the patho physiology of neurodegeneration in PD and increased target specificity, together with subsequent careful pharmaco kinetic, toxicology and safety studies, could aid the decision as to which patients might benefit from target-specific neuroprotective or neurorestorative therapies. 4, 6 Lack of accurate animal models
Toxin-based models
The most widely used animal models of PD comprise mice and nonhuman primates in which PD-like motor symptoms have been induced through local administration of neurotoxin 6-hydroxydopamine (6-OHDA) or systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In another commonly used model, bacterial endotoxin lipopolysaccharide is injected directly into the rat nigrostriatal path way to produce selective degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), which results in a parkinsonian syndrome. 7, 8 Other less frequently used neurotoxin models involve administration of rotenone, paraquat, isoquinoline derivatives, or meth amphetamine. 9 Though adequate at replicating the motor aspects of advanced PD, the fact that the neurotoxin-based animal models selectively damage dopaminergic neurons means they often do not exhibit the complex extra dopaminergic involvement and non motor dysfunction seen in early PD. Also, the pathological hallmark of PD-the presence of Lewy bodies-has not consistently been observed in these neurotoxin models. 9 Although some rhesus monkey MPTP-based models mimic the changes in extrastriatal dopamine, noradrenaline and 5-hydroxytryptamine levels that are typically observed in humans, 10 these models require acute administration of toxins, which is unlikely to reflect the chronic and progressive nature of Key points ■ Incomplete understanding of the pathogenesis of Parkinson disease (PD), lack of accurate animal models and validated biomarkers, and limitations in trial design impede the development of effective neuroprotective therapies for PD ■ Novel transgenic animal models, adaptive and delayed-start trial designs, and identification of potential serum, cerebrospinal fluid and neuroimaging biomarkers are facilitating development and testing of effective disease-modifying therapies ■ α-Synuclein has a key role in the pathogenesis of PD; targeting of the formation and clearance of this protein has shown promising results in preclinical models ■ Possible approaches for targeting α-synuclein accumulation include direct blocking of α-synuclein aggregation, immunization against α-synuclein, and enhancement of its lysosomal clearance; these strategies are all still in their infancy ■ As 50% of patients with PD have comorbid Alzheimer disease (AD) pathology, targeting of tau and amyloid-β could open novel avenues to alleviate or halt cognitive dysfunction ■ Disease-modifying therapies under investigation in AD could also be of benefit in PD; repurposing of existing drugs for use in PD also warrants further investigation the neurodegenerative process in PD. Recent refinements to this technique, such as reduced doses of neurotoxin or intermittent dosing schedules, are now being successfully used to replicate the progressive p athology, and also to study compensato ry mechanisms.
11,12
Transgenic models Transgenic animal models can recapitulate monogenic mutations seen in patients with familial PD, and provide insights into selected molecular aspects of PD pathogenesis and early stages of the disease. Such models include transgenic mice overexpressing normal or mutated human α-synuclein (as seen in autosomal dominant familial PD) under the control of Thy1 (Thy1-aSyn mice) or Th promoters. A major limitation of transgenic models is that they do not consistently reproduce the expected pattern of nigrostriatal degeneration typically seen in PD. 13 One of the most elaborate models is the MitoPark mouse, in which Tfam-the gene encoding mitochondrial transcription factor A-is selectively removed from dopaminergic neurons, resulting in disrupted mitochondrial function and subsequent progressive loss of nigro striatal dopaminergic neurons, which manifests as PD-like motor phenotype. 14 . Although this particular model is not based on a genetic mutation seen in humans with PD, it might be useful in large-scale screening of potential therapeutic agents. 8 To reflect the growing evidence that misfolding of α-synuclein is a key contributor to the pathogenesis of PD, new mouse models have been developed in which a single injection of synthetic misfolded α-synuclein initiates a cascade of neurodegenerative events, leading to Lewy body-type inclusions, selective loss of neurons in the SNpc, and motor impairments, thereby replicating several aspects of PD pathophysiology. 15, 16 Although these animal models have enabled progress towards the discovery of novel treatments for the motor symptoms and complications of PD, and have contributed to our understanding of PD pathogenesis, it is early to judge whether they will be successful in aiding the development of disease-modifying or neuroprotective strategies. There is currently no 'best' model that perfectly captures the chronic neurodegeneration and clinical pheno types seen in PD. Investigators must understand the limitations of various models and may need to choose a specific model corresponding to a specific research question (such as targeting of mitochondrial dysfunction versus targeting of α-synuclein transmission) or develop an agent that has reproducible efficacy across multiple animal models.
Challenges in clinical trials

Limitations in trial design
The design of clinical trials might contribute to the lack of translation from encouraging results in preclinical models to human patients. Current trial designs might be insufficiently sensitive to identify disease-modifying effects, or might struggle to convincingly separate such effects from long-lasting symptomatic relief.
Washout trial designs attempt to eliminate and separate any potential symptomatic effects from diseasemodifying effects; however, if the washout period is too short, uncertainty often remains regarding whether any of the observed beneficial effects could be due to unanticipated long-lasting symptomatic effects. In the ELLDOPA trial, for example, the short washout period of just 2 weeks is one putative explanation for an apparent disease-modifying effect of levodopa. 17 However, a long washout period-several months or longer-could be confounded by the progressive nature of PD, and risks high levels of patient dropout. 18 Delayed-start trial designs, as used in the ADAGIO trial to assess the disease-modifying potential of rasagiline, are a promising alternative to washout trials. One disadvantage of the delayed-start design is that the initial phase must be long enough for the neuroprotective effect to occur in patients receiving the trial drug from the outset, which raises ethical concerns of drug-naive patients remaining on placebo for an extended period. In addition, different patient dropout rates between randomized groups can affect the statistical analysis of results, particularly given that the expected differences between the earlystart and delayed-start patients groups are often small owing to the slowly progressive nature of PD. 19 Longitudinal study designs with composite global meas ures that evaluate a range of motor and non motor symptoms for a multidimensional assessment of disease progression over a long time period, typically a number of years, are the most effective approach to evaluate neuroprotective or disease-modifying therapies. 20 However, such trials require considerable investment, and extensive collaboration between drug companies, research institutes and clinical centres is needed to manage the costs.
Suboptimal patient selection
Drug-naive patients with recently diagnosed PD are commonly selected as the primary population to be included in clinical trials, because they are thought to have a higher proportion of salvageable neurons than do patients with more-advanced disease. 21 A postmortem study published in 2013 quantified the extent of nigrostriatal degeneration from time of diagnosis to up to 27 years after diagnosis. 22 The study showed that dopaminergic neurons in the fibres of the dorsal putamen were already reduced in number at diagnosis, and were virtually absent as early as 4 years after diagnosis. Any clinical deterioration after this time is thought to represent loss of compensatory mechanisms or degeneration of nondopaminergic neurons. These data have obvious implications for patient selection for future trials, and might also indicate that previous trials with apparently negative results were conducted in patients with too few surviving dopaminergic neurons. Ideally, patients enrolled for neuroprotective trials should be at an early stage of disease, so that they have a sufficient number of surviving neurons for benefits to be demonstrable.
A caveat to recruitment of early-stage patients is that they are typically more difficult to identify than advancedstage patients, and the risk of including misdiagnosed patients or patients with atypical forms of parkinsonism such as progressive supranuclear palsy, multiple system atrophy or corticobasal degeneration is high. Furthermore, in 10% of patients with a clinical diagnosis of early PD, dopaminergic functional imaging scans show no evidence of dopaminergic deficit. 23 Disease severity at presentation and rate of disease progression can also vary: older age at disease onset is associated with higher levels of disability on the Hoehn and Yahr scale, and tremor-dominant PD is associated with slower disease progression and less-severe cognitive impairment than is akinetic rigid PD. 24 Conversely, patients with moderate to advanced PD, who are more likely to have measurable end points on validated scales than are newly diagnosed patients, can have such advanced neurodegeneration that neuroprotective agents might be 'too little, too late' . A 2013 study, however, showed continued survival of melanincontaining neurons in the SNpc that persisted long into the disease (decades after diagnosis), which was in stark contrast to the rapid decline in the number of neurons immunoreactive to tyrosine hydroxylase (a common marker of dopaminergic neurons), perhaps indicating failure of neuronal protein expression and/or function rather than neuronal death. 22 Neurotrophic or regenerative therapies might, therefore, be of benefit even in advanced stages of the disease.
Although early intervention provides the greatest likelihood of a response to any neuroprotective treatment, there will always be a need to identify neuroprotective treatments that are helpful in the population with clinically manifest disease. It is also important to identify whether neuro protective treatments could be tolerated in conjunction with symptomatic agents such as levodopa, and whether they can delay or prevent the development of major disabilities in PD, such as freezing, falls and dementia.
Difficulty choosing the most effective dose
Doses of experimental therapies for use in human trials are often chosen to replicate plasma concentrations in successful animal experiments; however, the plasma concentrations do not necessarily correlate with concentrations in the brain and bioavailability at the receptor level. Adding to the uncertainty, results from various animal models are often conflicting, or a drug might be effective only within a narrow dose range. A lack of validated bio markers makes it difficult to titrate varying doses or ascertain the most effective dose range. The use of adaptive trial designs could enable a large number of varying doses to be tested at the initial stage (with a progressive focus on the most encouraging doses) without negatively affecting the long-term results. 25 The need for validated biomarkers No validated, sensitive biomarker for the diagnosis and monitoring of treatment response in PD has been developed. In 2013, the Parkinson's Progression Markers Initiative published encouraging results showing that cerebrospinal fluid (CSF) levels of Aβ , total tau, tau phosphorylated at Thr 181 , and α-synuclein were lower in patients with early (duration <2 years), drug-naive PD than in healthy controls, suggesting prognostic and diagnostic value. 26 7 T MRI, novel MRI sequences that combine diffusion tensor imaging, T2*-weighted and whole-brain T1-weighted techniques, novel PET ligands, and transcranial ultrasound have all shown promise in identification of patients with PD, but imaging markers for PD are still at an early stage. 27 
Insensitive end points and outcome measures
The lack of reliable CSF, blood and imaging biomarkers means that clinical trials have to rely on clinical end points or symptomatic markers to assess disease progression. The time taken for a drug-naive patient to require dopaminergic or symptomatic therapy is often used as evidence of disease progression, and although this is a well-defined, measurable end point that is not confounded by symptomatic effects from other drugs, 28 a notable limitation is that in clinical practice, the decision to start symptomatic therapy relies on a number of factors that depend on the patient, physician and care centre. The time to require therapy, therefore, does not necessarily correlate with disease stage or rate of progression, and it is often impossible to differentiate whether a delayed need for symptomatic treatment reflects symptomatic or neuroprotective effects of the studied drug. 28, 29 Another commonly used method is repeated assessment with the Unified PD Rating Scale (UPDRS). Although intra-rater and inter-rater variability should not be overlooked, the most recent version of this scale (MDS-UPDRS)-in combination with other scales to evaluate gait and dyskinesia and nonmotor symptoms, such as cognition, mood and sleep-can aid evaluation of drug efficacy, particularly when the different rating scales concordantly indicate beneficial effects.
Prohibitive cost of drug development
The development of a new therapy takes approximately 15 years and costs around US$1.2 billion. 30 Despite the potential commercial value of an effective diseasemodifying therapy for PD, this area of research is considered high-risk within the pharmaceutical industry owing to the high costs of clinical trials and the lack of any positive results to date.
High-throughput cell-based drug screening is a technology developed to overcome the high development costs. Yeast cells engineered to express α-synuclein in a way that captures the cellular pathology in PD have recently been used to screen more than 190,000 compounds for potential neuroprotective effects, leading to the identification of a new potential pharmaceutical target, the E3 ubiquitin ligase, and a novel molecule, the N-aryl benzimidazole analogue NAB2, which showed neuroprotective effects in three different animal models of PD. 31, 32 High-throughput screening of drugs already licensed for human use to assess their potential for repurposing is an appealing approach; indeed, this technology has recently shown that ursodeoxycholic acid, which is already licensed for use in liver disease, improves mitochondrial function, and a phase IIa trial is already planned and pending funding. 33 Other nonmammalian transgenic models of PD, such as Drosophila melanogaster and zebrafish, are also in use as a low-cost, high-throughput method to screen novel compounds. 8 
Targets for neuroprotective therapies
Of the various cellular mechanisms involved in the pathogenesis of PD, calcium homeostasis, oxidative stress, mitochondrial dysfunction, autophagy, and formation and clearance of α-synuclein all represent targets for putative neuroprotective therapies (Figure 1 ), some of which are currently being tested in clinical trials (Table 2) .
Calcium channel blockade
The apparent selective vulnerability and degeneration of dopaminergic neurons of the SNpc in PD could be related to high energy demands associated with calcium Nature Reviews | Neurology Figure 1 | Proposed mechanisms involved in the Parkinson disease pathogenesis, and targets for intervention. Potential strategies for intervention include modulation of native coils of α-synuclein expression (1), upregulation of chaperone molecules to promote clearance of α-synuclein (2), upregulation of enzymes such as protein phosphatase 2A that enhance dephosphorylation of α-synuclein at Ser129 (3), facilitation of the ubiquitin-proteasome system to clear unwanted α-synuclein (4), enhancement of liposomal function and α-synuclein metabolism by increasing GCase activity (5), direct enhancement of toxic α-synuclein clearance by active and/or passive immunization (6) or by blocking its aggregation, prevention of the propagation of α-synuclein from affected to unaffected cells (7), inhibition of Ca V 1.3 to reduce calcium influx (8) , inhibition of NMDA receptors to limit activation of excitatory pathways (9), inhibition of inflammatory pathways (10), upregulation of SIRT1 to enhance mitochondrial biogenesis and reduce activation of proinflammatory pathways (11), inhibition of oxidative stress pathways (12) , reduction of iron accumulation (13) , and inhibition of apoptotic pathways (14) . Grey boxes feature drugs thought to act on these pathways. Abbreviations: GCSF, granulocyte colony-stimulating factor; NMDA, N-methyld-aspartate; PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1-α; SIRT1, NAD-dependent protein deacetylase sirtuin-1. AFFITOPE® is a registered trademark of AFFiRiS, Austria.
influx through Ca V 1.3 L-type calcium channels (LTCC) during their autonomous pacemaking function, leading to increased mitochondria-mediated oxidative stress and subsequent cell death. 34 Ca V 1.3 channel expression is increased in the cerebral cortex of patients with early-stage PD (before the appearance of pathological changes), implicating disturbed calcium homeostasis as an early event in PD pathogenesis rather than a consequence of neurodegeneration. Calcium homeostasis is, therefore, an attractive target for neuroprotective therapies. [154] [155] [156] [157] Halted loss of DA neurons in some 6-OHDA, MPTP and rotenone models; conflicting results and doses [158] [159] [160] [161] Human trials conflicting: beneficial in four trials, no effect in other four trials, worsening motor function in one trial 155 Granulocyte colonystimulating factor Antiapoptotic (activates antiapoptotic STAT3 and AKT pathways) Neurotrophic factor promotes neurogenesis through reciprocal interaction with vascular endothelial growth factor activation Protected DA cells from apoptosis, 212 showed neurotrophic properties, 213 stimulated neurogenesis 214 and inhibited proinflammatory pathways in vivo 215 Prevented dopaminergic degeneration in vivo in MPTP models of PD, though at doses higher than those likely to be tolerated in humans 216, 217 No clinical data yet
Erythropoietin
Anti-inflammatory properties Protected DA neurons and inhibited proliferation of astrocytes in vitro 218 Reduced inflammation in DA neurons in 6-OHDA models in vivo 218 Improved UPDRS III in a phase I trial of 10 patients; results persisted for 30 weeks 219 No effect on motor symptoms but some benefits for cardiovascular autonomic function and cognition in an RCT of 26 patients Epidemiological data indicate that patients treated with centrally acting calcium channel blockers could have a reduced risk of developing PD, [36] [37] [38] although this idea remains controversial. 39 One candidate for a calcium channel modulator that could be of benefit in PD is isradipine, which has a high affinity for Ca V 1.3 and is licensed for the treatment of hypertension. Despite strong evidence from preclinical studies of PD, 40, 41 however, a recent randomized controlled trial (RCT) in which patients were treated with 10 mg isradipine for 12 months suggested only a modest advantage of questionable clinical relevance (around 1 point in the total UPDRS score). Of note, this trial was not powered for assessment of efficacy. 42 Furthermore, according to preclinical data, the most robust neuroprotective effects of isradipine are seen at doses much higher than would be tolerated in humans-a possible limitation to the therapeutic potential of this drug. 40 Nevertheless, a fully powered phase III trial to assess the efficacy of isradipine (10 mg per day) in PD has received a $23,000,000 grant from the NIH, and will start recruiting patients in 2014. Emerging candidates from preclinical studies include novel, highly selective Ca V 1.3 antagonists that might offer more-promising results without the adverse effects that accompany general antagonism of LTCCs. 43 Zonisamide, a drug that is used for the adjunctive treatment of epilepsy, is thought to inhibit voltage-gated sodium channels and calcium channels that mediate neur onal depolarization-induced glutamate release. 44 This drug, which also enhances dopamine release, is licensed in Japan as an adjunctive treatment for motor symptoms in PD, and is currently being investigated in parallel for its neuro protective potential. 45 Zonisamide has demonstrated symptomatic benefits in doses of 25-100 mg, but preclinical data regarding neuroprotective equivalent doses are conflicting, and some investigators used serum concentrations well above what could be achieved with the maximal tolerable dose in humans. 46 A phase II trial is currently underway (ClinicalTrials.gov identifier NCT01766128), but separation of symptomatic benefits from neuroprotective effects might be difficult.
Reducing oxidative stress
Oxidative damage resulting from failure of endogenous protective mechanisms, dopamine metabolism, defective mitophagy, and accumulation of mutations in the mitochondrial DNA is thought to have an important role in the pathogenesis of PD. Indeed, postmortem studies have provided evidence of oxidative damage in the substantia nigra of patients with PD. 47 Reduction of oxidative stress with antioxidants selegiline, rasagiline and vitamin E have not convincingly or consistently demonstrated diseasemodifying effects, 48, 49 but various other antioxidants are currently being investigated in clinical trials.
Increasing urate levels
According to epidemiological data, individuals with high levels of serum urate, a natural antioxidant, have a 33% lower risk of developing PD than do people with normal levels of urate. [50] [51] [52] Moreover, high levels of urate in serum and CSF of patients with early PD are associated with a reduced rate of clinical and radiological progression. [53] [54] [55] Raising the serum urate level through oral administration of the urate precursor inosine 56 could be a potential neuroprotective therapy for PD. In a recent RCT, inosine treatment was well tolerated, and was associ ated with a favourable rate of progression on the basis of changes in UPDRS scores over 24 months. 57 After adjustment for baseline differences, however, the change amounted to only 1 point per year on the total UPDRS scale. Although the trial was not powered to determine efficacy, no difference in time to require dopaminergic therapy was observed between groups, and few patients reached the 2-year time point. Further funding is currently being sought for a larger phase III trial. It should be kept in mind that elevated serum urate has been shown to increase the risk of hypertension, coronary heart disease, gout and stroke over the long term, which is potentially problematic for older patients with PD and could limit the utility of inosine. 58 Reducing iron accumulation Sporadic PD and autosomal recessive juvenile parkinsonism are both associated with excessive iron accumulation in the SNpc, 59 and MRI and transcranial ultrasonography studies in patients with PD show that increased levels of iron in the basal ganglia and substantia nigra correlate with motor severity, 60 potentially by inducing oxidative stress and aggregation of misfolded α-synuclein. 61 Alleviation of oxidative stress by suppressing iron ac cumulation could potentially be beneficial in PD.
Strong evidence from preclinical studies supports the neuroprotective effects of deferiprone, a chelating agent licensed for the treatment of peripheral iron overload disorders. [62] [63] [64] A recent delayed-start trial demonstrated that deferiprone reduced disability on the UPDRS motor subscale in the early start group (−2.3 ± 0.6) compared with the delayed start group (+1.0 ± 0.7). The improvement was sustained at 12 months, although the improvements waned after 18 months of continuous treatment. 65 Whether excessive iron represents a cause or a consequence of dopaminergic neuronal cell death is uncertain, and even though the recently reported efficacy of deferiprone is highly encouraging, it remains to be seen whether its clinical benefits occurred as a result of iron chelation alone or via permissive effects of chelation on dopaminergic treatments. Two further phase II/III trials are now underway (ClinicalTrials.gov NCT01539837 and NCT00943748).
Glutathione
Glutathione is a tripeptide that, besides being a neurotransmitter, is an essential contributor to the primary antioxidant system of the brain. 66 Prolonged depletion of glutathione inhibits the activity of mitochondrial complex I. 67 Glutathione depletion is seen in the substantia nigra of patients with PD, 68, 69 and also in patients with incidental Lewy body disease, suggesting that loss of gluta thione occurs early in the pathogenesis of PD. 70 Previous efforts to increase glutathione levels via intravenous administration in patients with PD have been unsuccessful, presumably because glutathione crosses the blood-brain barrier via a saturable mechanism and is not efficiently taken up by neurons.
66,71
N-acetylcysteine, which is commonly used as a mucolytic, is an oral precursor to glutathione, and decreases α-synuclein aggregation in transgenic mouse models of PD. 72 In a pilot human trial, orally administered N-acetylcysteine was well tolerated, and raised the levels of glutathione in CSF. 73 Although findings in transgenic models are encouraging, no efficacy data in humans exist. Notably, a trial using oral N-acetylcysteine in patients with early Alzheimer disease (AD) failed to improve any primary outcome measures. 74 Given that glutathione depletion seems to occur early in the pathogenesis of PD, the best approach would be to evaluate glutathione replacement among patients at the very early-ideally, presymptomatic-stage of disease.
Enhancing mitochondrial function
Considerable evidence from genetic, animal and postmortem studies implicates mitochondrial dysfunction in the pathogenesis of PD. 75 Mitotoxic drugs can cause parkinsonism, and mutations in PARK2, PARK7 and PINK1-found in autosomal recessive forms of PD-impair mitochondrial autophagy.
The selective vulnerability of nigrostriatal neurons could be related to their high metabolic demands. Enhance ment of mitochondrial biogenesis to counteract the effects of neurodegeneration is a reasonable strategy, but recent trials using mitochondrial enhancers such as creatine and mitoquinone have all failed to convincingly demonstrate disease-modifying effects. Possible reasons for this failure include poor brain penetrance, and inclusion of patients with neurodegeneration that is too advanced for neuroprotective compounds to be of benefit. Growing evidence suggests that mitophagy and mitochondrial calcium homeostasis could be more important for maintenance of mitochondrial biogenesis than was previously thought, and could be better targets for intervention. 76 PGC-1α is a protein that interacts with peroxisome proliferator-activated receptor γ (PPARγ) to control mitochondrial and microglial function, and acts with SIRT1 to upregulate mitochondrial biogenesis. 77 Modulation of the PGC-1α-PPARγ-SIRT1 network, therefore, is a potentially attractive approach for intervention in PD. In vivo studies have shown that resveratrol, which upregulates SIRT1 expression, protects dopaminergic neurons from degeneration induced by MPTP and 6-OHDA, possibly via modulation of autophagy and proinflammatory pathways. 78, 79 Although no clinical data exist, there is a sufficient indication of potential benefit to merit further in vivo studies.
A recently developed high-throughput screening method that uses cultured nerve tissue from patients with PD has revealed that urosdeoxycholic acid can rescue mitochondrial dysfunction. The findings were corroborated in cultured mutant fibroblasts expressing PARK2 and LRRK2, and urosdeoxycholic acid was neuroprotective in a transgenic mouse model of AD, leading to the compound being fast-tracked to a phase II trial. 33 
Suppressing neuroinflammation
Inflammation is increasingly recognized as a key contributor to the pathogenesis of PD. According to epidemiological studies, NSAID use confers a decreased risk of PD. 80 PET imaging of patients with PD shows increased microglial activation, 81 and elevated levels of proinflammatory medi ators are seen in the substantia nigra at post mortem examination. 82 Moreover, genome-wide association studies have linked certain HLA alleles with the risk of PD. 83 Agents that target these inflammatory pathways are currently being investigated in clinical trials.
Pioglitazone
Pioglitazone is licensed for treatment of type 2 diabetes, and is thought to activate PPARγ. 84 This drug has demonstrated anti-inflammatory, neuroprotective benefits in animal models of AD, 85 epilepsy, 86 stroke 87 and ALS. 88 Owing to its demonstrated efficacy across several toxinbased animal models and influence across multiple cellular pathways, 89-91 a phase II trial is currently underway (ClinicalTrials.gov NCT01280123); however, the potential of pioglitazone might be limited by adverse effects and an association with the development of bladder cancers. [92] [93] [94] [95] Many of the metabolic effects of pioglitazone might occur independently of PPARγ and involve binding to mitochondrial target of thiazolidinones (mTOT), a complex on the inner mitochondrial membrane that directly influences mitochondrial function. 96, 97 Novel compounds that bind to mTOT are being tested in animal models of PD, and might offer similar benefits to pioglitazone, but with fewer adverse effects. 98 Myeloperoxidase Myeloperoxidase, a haem enzyme expressed in a variety of phagocytic cells, is thought to have an important role in α-synuclein-mediated toxicity. Following α-synucleininduced activation of microglia, myeloperoxidase mediates production of proinflammatory molecules and promotes misfolding of normally folded α-synuclein, leading to further aggregate formation in previously unaffected neurons. 99 Myeloperoxidase expression in microglia is found to be upregulated in the ventral midbrain of patients with PD and mice exposed to MPTP. 100 Inhibition of myeloperoxidase has been hypothesized to slow down neurodegeneration in PD, given that ventral midbrain dopaminergic neurons of transgenic mice that are deficient in myeloperoxidase show an increased resilience to MPTP-induced cytotoxicity. In a recently completed RCT, AZD3241-a novel myeloperoxidase inhibitorwas well tolerated and decreased plasma myeloperoxidase ac tivity, 101 but no efficacy data have been obtained.
Statins
Statins not only lower cholesterol levels, but also have marked anti-inflammatory effects. In vitro studies show that simvastatin can reduce α-synuclein aggregation, and inhibit the formation of tumour necrosis factor and peroxynitrite in activated microglia. Moreover, statins have been shown to protect dopaminergic neurons from inflammatory damage in vitro via modulation of N-methyl-d-aspartate receptors. In lipopolysaccharide and MPTP models of PD, statins prevent dopaminergic degeneration. [102] [103] [104] [105] [106] [107] Epidemiological data regarding statin use and risk of developing PD are contradictory: some studies report a reduced incidence of PD in association with statin use, [108] [109] [110] whereas others have found no correlation [111] [112] [113] or have reported an inverse correlation between LDL cholesterol levels and PD risk. 114 The variability is possibly explained by early studies not accounting for confounders such as comorbid diabetes and use of NSAIDs and calcium channel blockers, all of which can modulate the risk of PD. However, a recent populationbased study, adjusted for most confounders, showed that patients on continued lipophilic statin therapy had a reduced incidence of PD compared with people who stopped their medication, 115 although further longitudinal studies are needed to confirm the finding. No clinical data regarding statin treatment in PD exist, but promising in vivo and in vitro data have indicated potential neuroprotective mechanisms of statins, which should fuel further clinical studies.
Targeting α-synuclein Mutations and variations in the α-synuclein gene can cause familial PD and contribute to sporadic PD, and overexpression of α-synuclein in transgenic mice leads to a parkin son ian phenotype. 13 The presence of Lewy bodies and Lewy neurites, of which α-synuclein constitutes a major component, is the pathological hallmark of PD. The conversion of α-synuclein from soluble monomers to aggregated, insoluble forms has been established as a key event in the pathogenesis of PD. 116 Postmortem studies of fetal mesencephalic brain tissue grafted into brains of patients with PD showed evidence of Lewy body-like inclusions in the host tissue, 117 suggesting that α-synuclein can transfer to unaffected cells and might act as a prion-like protein. This prion-like propagation of α-synuclein has subsequently been confirmed in vitro and in vivo, 15, [117] [118] [119] [120] but there are currently no strategies to stop its propagation. Targeting the formation and clearance of α-synuclein within neurons to protect them against neurodegeneration is a promising avenue that is gathering great interest. α-Synuclein is normally cleared from the cell by the ubiquitin-proteasome or autophagylysosomal systems, and defects in these systems have been identified in patients with PD. 6 Small peptides, vector-mediated RNA interference, and novel molecules such as ELN484228 that can directly block α-synuclein aggregation 121 have all shown promise for modulation of α-synuclein formation and clearance in preclinical studies, but are still early in development.
Immunization against α-synuclein
Another potential therapeutic strategy is to reduce the amount of the insoluble, toxic form of α-synuclein. Both active and passive immunization with monoclonal antibodies against α-synuclein promoted reduction and clearance of α-synuclein and rescued behavioural deficits in transgenic mice overexpressing human α-synuclein. 122, 123 These data has led to two commercially funded research programmes. PRX002-an antibody against the C-terminus of α-synuclein-has major sup port pledged by Roche, with a phase I trial testing the safety and tolerability of PRX002 in healthy individuals in progress (ClinicalTrials.gov NCT02095171). AFFITOPE® PD01 (AFFiRiS, Austria), a peptide-carrier conjugate vaccine developed to induce antibodies selectively against α-synuclein, is currently in phase I clinical testing in patients with PD (ClinicalTrials.gov NCT01568099).
On a cautionary note, similar efforts using immunization are at a more advanced stage in AD, but previous trials targeting Aβ in patients with AD were discontinued early owing to a substantial number of meningoencephalitis cases. These discouraging experiences have led to concerns that antibodies could alter the physiological function of other synucleins or trigger autoimmunity, thereby exacerbating PD pathology. However, unlike Aβ, α-synuclein does not deposit in leptomeningeal and cortical blood vessels, and short-peptide vaccines that do not trigger T-cell autoimmunity or crossreact with other synucleins should, at least theoretically, carry lower risks than Aβ vaccines. 124 Modulation of α-synuclein phosphorylation α-Synuclein phosphorylated at Ser129 represents the most abundant form of α-synuclein found in Lewy bodies, and kinase inhibitors have been specifically designed to inhi bit α-synuclein phosphorylation. 125 However, as several different kinases are capable of phosphorylating α-synuclein, substantial amounts of Ser129-phosphorylated α-synuclein would still be produced after treatment with a drug that inhibits a single kinase. Modulation of enzymes that enhance dephosphorylation of Ser129, such as protein phosphatase 2A (PP2A), might be an alternative therapeutic strategy. 126 Metformin, a drug that is used to treat type 2 diabetes, has recently been shown to reduce levels of phosphorylated α-synuclein in vitro and in vivo by inhibiting mammalian target of rapamycin (mTOR) and upregulating PP2A activity. 127 Interestingly, although epidemiological data regarding the association between PD and diabetes are conflicting, a recent prospective cohort study showed that the incidence of PD was increased almost twofold in a Taiwanese population with type 2 diabetes. The increase was exacerbated by the use of sulphonylureas, but the risk was mitigated by the use of metformin therapy. 128 These emerging data are prompting further studies to investigate the disease-modifying properties of metformin.
Promoting lysosomal clearance of α-synuclein
Enhancement of α-synuclein clearance by modulating ubi quitin and lysosomal recycling pathways is another pro mising strategy. The identification of heat shock pro teins that act as chaperones and promote the transfer of excessive α-synuclein to the ubiquitin-lysosomal systems for clearance has led to the testing of compounds that could stimulate this pathway. The antihistamine latrepirdine increases autophagy and reduces accumulation of α-synuclein in vitro and in vivo, and further testing is underway. 129 NAB2, a novel small molecule, has recently been shown to promote endosomal transport by activating the ubiquitin ligase Rsp5-Nedd4 pathway in vitro; NAB2 'resets' vesicle tracking homeostasis and reverses multiple pathological changes caused by α-synuclein. 31, 32 GCase is an enzyme involved in regulation of lysosomal function and α-synuclein folding. Mutations in the GCaseencoding gene GBA1 are observed in up to 25% of patients with young-onset PD.
130 GBA1 mutations are associated with reduced GCase activity and increased neo cortical accumulation of α-synuclein aggregates. 131 Reduced levels of GCase activity are seen in the substantia nigra of patients with sporadic PD, and increased expression of α-synuclein in cultured cell models of PD is associated with reduced GCase activity, suggesting a bidirectional relationship. 132 Increasing the activity of GCase might increase α-synuclein metabolism and reduce its accumulation. In a transgenic mouse model overexpressing Ala53Thr α-synuclein, intracerebral injection of GCase via an adeno-associated virus vector increased activity of GCase, reduced accumulation of α-synuclein and tau, and reversed cognitive deficits. 132 In vitro studies have shown that ambroxol, a secretolytic agent licensed for the treatment of respiratory diseases, acts as a chaperone. [133] [134] [135] Ambroxol stabilizes misfolded GCase, allowing it to pass through the endoplasmic reticulum to the lysosome, which increases the activity of GCase and, potentially, the clearance of α-synuclein. A novel synthetic chaperone, AT2101, improved motor and non motor function, abolished microglial inflammatory response in the substantia nigra and reduced α-synuclein immunoreactivity in nigral dopaminergic neurons of Thy1-aSyn mice. 136 These new potential targets and preliminary results from preclinical studies are encouraging, but we should keep in mind that these novel compounds are still at an early stage of development.
Other strategies
Compounds that affect multiple pathways
In vitro and in vivo data suggest that GM1 ganglioside, a component of neuronal cell membranes, affects multiple pathways implicated in the pathogenesis of PD. In animal models of PD, GM1 modulates intracellular calcium homeostasis, mitochondrial function and lysosomal integrity, and prevents aggregation of α-synuclein. [137] [138] [139] Purified GM1 is well tolerated, and has shown encouraging effects on motor function in two well-designed, placebocontrolled clinical trials, 139 ,140 but we cannot conclude from the existing data that the long-term effects are more than symptomatic. GM1 is currently produced from bovine brain tissue, which has also raised public safety concerns owing to the possibility of contracting Creutzfeld-Jakob disease. Ovine sources and synthetic analogues are currently being investigated as alternatives to bovine GM1.
Compounds with unknown mechanism of action
Exenatide is a synthetic glucagon-like peptide-1 (GLP-1) agonist that improves glycaemic control via activation of the GLP-1 receptor, and is licensed for the treatment of type 2 diabetes. 141 The role of the GLP-1 receptor in the CNS is unclear, but in vitro GLP-1 receptor stimulation with exenatide produces neur oprotective, anti-inflammatory and antiapoptotic effects; exenatide also has neurotrophic properties, stimulates mitoc hondrial biogenesis, and enhances synaptic plasticity. 142, 143 Exena tide has exhibited neuroprotective and neuro restorative effects in multiple in vivo toxin models of PD in doses comparable to those used to treat dia betes in humans. The beneficial effects of exenatide might be caused by its anti-inflammatory 144, 145 or neurogenesis-stimulating properties. 146 Exenatide has also been demonstrated to ameliorate nondopaminergic impairments, improve learning and memory performance, and reverse nonmotor behavioural impairments in rodent models of PD and AD. 147, 148 In a small open-label RCT, exenatide exposure in patients with PD led to a mean 7.0-point advantage on the MDS-UPDRS Part III motor scale; the improvements persisted after a 12-month washout period. 149, 150 Scores on the Mattis Dementia Rating scale indicated an improvement that persisted after 12 months; Montgomery-Åsberg Depression Rating Scale scores improved, but did not reach statistical significance. Though clearly encouraging, the existing data are from open-label trials and, thus, should not be interpreted as proof of efficacy in PD. A great deal of mechanistic uncertainty regarding exenatide prevails, and the drug has been linked to a small increase in risk of pancreatitis in patients with diabetes. 151 A larger, double-blind trial with a once-weekly, longacting form of exenatide is underway (ClinicalTrials.gov NCT01971242).
In view of consistent epidemiological studies suggesting a 50% reduced risk of PD in smokers, 152, 153 nicotine is being investigated for its potentially disease-modifying properties. In vitro data suggest that nicotine could provide neuroprotection by inhibiting α-synuclein fibrillation and reducing oxidative stress, 154, 155 and stimulation of the a7, a4B2 and a4 subunits of the nicotinic acetylcholine receptor modulates inflammatory pathways and calcium homeostasis. 156, 157 Studies assessing the efficacy of nicotine in animal models of PD have discrepancies regarding dose and dosing regimen, [158] [159] [160] [161] and report conflicting results. Even taking into account the differences in methodology, the results are inconclusive at best. Results from human trials suggest a beneficial role in terms of reducing dyskinesia, but evidence for neuroprotection is as yet unconvincing. Nevertheless, an RCT using transdermal nicotine patches in 40 patients with PD has been completed; the results are yet to be published (ClinicalTrials.gov NCT00873392).
Repositioning of existing drugs
Many agents have failed phase I clinical trials because of toxicity. Evaluating the potential for drugs already licensed for human use to be repurposed for PD should, therefore, be a priority. The Linked Clinical Trials initiative, 162 launched by the Cure Parkinson's Trust, could aid identification of licensed drugs that might be repositioned for PD and, together with data from animal models, could facilitate prioritization of large-scale investments. According to the Linked Clinical Trials initiative, seven of 26 potential interventions-exenatide, liraglutide, lixisenatide, deferiprone, deferasirox, simvastatin and trehalose -were considered worth moving forward into small, 'parallel learning' clinical trials in patients with PD. 162 
Counteracting cognitive decline
Cognitive dysfunction can severely affect quality of life. In the advanced stage of PD, dementia is common, affecting up to 80% of patients, 163 and it often heralds impending residential care and mortality. It is important to note, however, that cognitive deficits are seen in 24% of patients by the time of diagnosis, 164 and mild cognitive impairment can occur early in the course of PD. 2 Cognitive decline can worsen the effects of motor disability, and at all stages of the disease, cognitive symptoms contribute subtantially to reduced quality of life. 2 Enhancing neurotransmitter function Historically, augmentation of depleted neurotransmitter reserves has been a more feasible treatment strategy for PD dementia (PDD) than targeting of molecular mechanisms involved in PD pathogenesis. Memantine-first developed for the treatment of AD-facilitates cholinergic, glutamatergic, serotonergic and dopaminergic signalling, but its efficacy in PDD is unclear. Rivastigmine, an acetylcholinesterase inhibitor, is the only licensed therapy for cognitive symptoms in PDD or dementia with Lewy bodies (DLB). A recent Cochrane review has confirmed that this drug improves cognition, behavioural disturbance and ability to perform activities of daily living. 165 Unfortunately, acetylcholinesterase inhibitors often worsen motor deficits and, as symptomatic treatments, do not affect the progression of the disease.
Despite the unmet need for treatment of cognitive dysfunction in PDD and DLB, only two drugs-donepezil, an acetylcholinesterase inhibitor, and atomoxetine, a selective noradrenaline reuptake inhibitor-are in advanced-stage clinical trials. Both drugs have been shown to improve cognition and behaviour in animal models of PD, and are currently being tested in phase II/III clinical trials in patients with PDD. To date, no clinical trials have investigated potential disease-modifying therapies in PDD or DLB. 166 Modulation of α-synuclein, Aβ and tau The neuropathology of PDD is heterogeneous, and multiple disease mechanisms have been implicated. Spreading of α-synuclein, possibly via prion-like propagation from the brainstem to limbic and neocortical structures, is thought to be a major contributor to dementia in PD, 167 making inhibition of the formation and propagation of α-synuclein an appealing strategy to halt cognitive and motor decline. However, 50% of patients with PDD also have Aβ plaques and hyperphosphorylated tau-containing neurofibrillary tangles characteristic of AD; this comorbid pathology could act synergistically with Lewy bodies and Lewy neurites and confer a poor prognosis. [168] [169] [170] [171] [172] Genetic studies have provided further support for the link between tau and PD: the H1/H1 subhaplotype of MAPT-the gene that encodes tau-has been associated with increased tau expression and susceptibility to AD in humans, 173 and poor memory performance in PD. 174 Genome-wide association studies have identified this subhaplotype as an independent risk factor for the development of PD 173, 174 and PDD. 176 
Inhibition of tau phosphorylation
The growing evidence supporting a role for tau in PD had led some to speculate that targeting of tau phosphory lation and formation might prevent cognitive decline, and that disease-modifying therapies developed for AD could benefit a subset of patients with PDD. Glycogen synthase-kinase 3b (GSK-3) is an enzyme involved in the phosphorylation of tau. Human trials assessing the efficacy of GSK-3 inhibitors have been disappointing. 166 For example, in a phase III RCT, valproate did not prevent agitation or psychosis in patients with AD. 177 Microdoses of lithium-previously shown to prevent oxidative stress-induced α-synuclein accumulation and neurodegeneration in a transgenic mouse model of PD 178 -prevented cognitive decline in patients with AD, 179 but adverse effects prevented follow-up.
Microtubule stabilization
Tau hyperphosphorylation has been speculated to reduce stabilization of microtubules, thereby exacerbating neuronal dysfunction. Small-molecule microtubulestabilizing drugs, which have long been used in cancer chemotherapy, are being investigated for potential repurposing for tauopathies. In aged transgenic mouse models with established tau pathology, epothilone D reduced tau pathology, prevented the loss of hippocampal neurons and synapses, and improved cognitive performance. 180 Although the results are encouraging, and might lead to identification of other small molecules that have microtubule-stabilizing effects and penetrate the bloodbrain barrier, these drugs are still at a very early stage of development and have not yet been tested in clinical trials.
Other tau-targeting strategies
According to data from a rodent rotenone model of PD, methylene blue derivatives have neuro protective properties and reverse behavioural deficits, possibly by rescuing mitochondrial function and redu cing formation of free radicals. 181 One of these compounds, TRx0237, reduced tau aggregation and inflammation and improved learning in the Morris water maze tests in mice in one study, 182 but other studies reported negative results. 183, 184 In phase II trials involving patients with AD, TRx0237 reduced the rate of cognitive decline; interestingly, no benefit was seen at high doses. 185 Phase III trials are currently underway.
Further considerations
Despite the encouraging number of compounds with potentially positive effects on cognition, numerous hurdles need to be addressed before effective diseasemodifying therapies against cognitive decline can be established. Importantly, greater understanding of the pathological process underlying cognitive dysfunction is required for identification of appropriate targets for intervention. Despite the established role of α-synuclein in the development of both motor and cognitive symptoms in PD, there is a marked heterogeneity among patients with PDD: 172 some nondemented patients with PD exhibit large amounts of cortical α-synuclein, 186 whereas some individuals with dementia have only minimal cortical α-synuclein accumulation at postmortem examination. 187 Furthermore, the interaction between Aβ and α-synuclein and the correlation between brain pathology and cognitive function remain to be elucidated. The timing of the intervention is also crucial: reduction of α-synuclein aggregation or tau hyperphosphorylation in individuals who are already symptomatic might not halt cognitive decline.
Biomarker studies indicate that patients with PDD are more likely to have increased CSF levels of total tau and decreased Aβ than are PD patients without cognitive decline, 188 and non-tremor-dominant patients have a propensity to develop dementia and manifest concurrent Aβ pathology. 189, 190 Further advances in biomarker studies that integrate CSF, neuroimaging and biochemical markers, together with identification of clinical subtypes of patients who are more likely to develop dementia, could enable clinicians and trial designers to select the most appropriate subgroup of individuals for early intervention.
Conclusions
Several drugs that have shown neuroprotective effects in neurotoxin-based animal models of PD have failed to demonstrate efficiency in recent high-profile clinical trials (Table 1) . Although the possibility remains that some of these approaches have beneficial neuroprotective effects in PD, no convincing data are available to support clinically relevant neuroprotection when the drugs are administered in isolation and according to the clinical trial protocols used. Several compounds that have shown promise in preclinical studies are currently being tested in clinical trials (Table 2 ) but, to date, double-blind data supporting clinical efficacy have not been found for any pharmacotherapies. Of the agents discussed in this Review, the growing evidence supporting the bene ficial effects of GLP-1 [142] [143] [144] [145] [146] [147] [148] [149] [150] agonists in a wide range of pathological processes has led some to speculate that this class of agents has the greatest potential to affect the progression of disease in PD.
High-throughput in vitro assays that screen for compounds to reduce α-synuclein aggregation or improve mitochondrial function can aid selection of the most promising agents for further testing, and in deciding which pharmacotherapeutic intervention strategies show the most promise. High-throughput screening can also open novel therapeutic opportunities: it seems increasingly likely that direct targeting of α-synuclein aggregation could become possible in the future, and upregulation of proteosomal or lysosomal systems, and/or promotion of chaperone molecules that can reduce α-synuclein aggregation might also become feasible. The most-promising compounds discovered in the high-throughput studies include ELN484228, 121 NAB2, 31,32 ursodeoxycholic acid 33 and AT2101. 136 Accurate detection of individuals who are at risk of developing PD is essential. When clinical symptoms appear, neurodegeneration might have already progressed beyond the reach of any neuroprotective agent. 22 Highly sensitive and specific biomarkers of PD are of the utmost importance, not only for early identification of individuals at risk and to reliably assess efficacy of potential treatments, but also to minimize the risk of exposing healthy people to adverse effects of PD pharmacotherapy.
The progression of symptoms in PD is heavily influenced by factors such as age, clinical phenotype and genotype. Classification of PD and other neurodegenerative diseases as clinicopathological entities rather than clinical syndromes could help stratify patients with PD. Individualized biomarkers of disease activity could more accurately gauge prognosis and aid tailoring of diseasemodifying therapies for individual patients, for example, those who are at increased risk of PDD.
Only one symptomatic therapy of modest effect is available for PDD, and no treatments have been proven to slow its progression. Growing genetic, biochemical and pathological evidence suggests that tau and α-synuclein are involved or share converging pathways in the pathogenesis of PD, [168] [169] [170] [171] [172] [173] [174] [175] [176] and influence development of cognitive impairment in patients with PD. The discovery of these convergent pathways has helped identify new targets-most importantly, tau phosphorylation and formation, and Aβ-for potential disease-modifying therapies, and has corroborated the notion that prevention of nigrostriatal degeneration as a sole strategy has limited potential in PDD. Combination treatment with agents that target multiple pathways could improve their efficacy. In long-term use, agents that harness neurodegenerative processes can have adverse effects, such as increased inflammation and/or reduced immunosurveillance for malignant change in peripheral tissues, and these aspects must be considered in the follow-up of patients exposed to these drugs.
Many of the agents discussed in this article have potential for further investigation; however, it remains to be seen whether any of them will prove to be effective neuroprotective therapies for PD. This said, the continued advances in many areas warrants optimism: one day, PD could be transformed from a continually progressive, disabling disease to a chronic but more manageable condition.
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